Neumora Therapeutics (NMRA) Cash & Equivalents (2022 - 2026)

Neumora Therapeutics has reported Cash & Equivalents for 5 years, with the latest figure at $147.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 15.93% year-over-year to $147.1 million; the trailing twelve-month figure through Mar 2026 stood at $147.1 million (up 15.93% YoY), and the FY2025 full-year result was $182.5 million, up 28.41% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $147.1 million, down from $182.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $412.3 million in Q3 2023, with the low at $124.5 million in Q2 2025.
• Average Cash & Equivalents over 5 years is $210.4 million, with a median of $182.9 million recorded in 2024.
• Year-over-year, Cash & Equivalents jumped 63.27% in 2023 and tumbled 62.0% in 2024.
• Tracing NMRA's Cash & Equivalents over 5 years: stood at $240.9 million in 2022, then soared by 55.24% to $374.0 million in 2023, then plunged by 62.0% to $142.1 million in 2024, then grew by 28.41% to $182.5 million in 2025, then slipped by 19.43% to $147.1 million in 2026.
• The last three Cash & Equivalents figures came in at $147.1 million (Q1 2026), $182.5 million (Q4 2025), and $129.1 million (Q3 2025), per Business Quant data.

Peer Comparison